首页> 美国卫生研究院文献>Nature Public Health Emergency Collection >Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment
【2h】

Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment

机译:儿童引起肺炎的致病菌的调查及其替比培南酯的治疗用途

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We investigated the usefulness of the novel oral carbapenem antibiotic tebipenem pivoxil (TBPM-PI) for treating bacterial pneumonia in children. Sputum and nasopharyngeal swabs were collected simultaneously, and causative organisms were identified by conventional bacterial culture together with exhaustive bacterial and viral identification by real-time polymerase chain reaction (PCR). The subjects were eight patients diagnosed with mild or moderate pneumonia at Sotobo Children’s Clinic Outpatient Department between October 2006 and June 2007. TBPM-PI was administered at the recommended clinical dose of 4 mg/kg b.i.d. to five patients and at a high dose of 6 mg/kg b.i.d. to three patients. Sputum was collected from all patients, and 11 strains were detected from washed sputum culture. Causative organisms were mainly (3 strains) and (6 strains), and nasopharyngeal swabs showed the same organisms as coughed-up sputum. Real-time PCR for individual viruses and identified four cases of only bacterial infection, one case of coinfection, two cases of viral coinfection, and one case of both viral and coinfection. The clinical results indicated efficacy in all patients, and causative organisms were 100% eliminated. In the four patients with only bacterial infection, the average fever of 38.9°C at the start of treatment normalized the following day, showing excellent efficacy. No clinically problematic adverse events occurred, and compliance was good. We consider that these cases provide valuable insights into the identity of pathogenic organisms of pneumonia in children and the possible role of TBPM-PI in outpatient treatment.
机译:我们调查了新型口服碳青霉烯类抗生素替比农仑匹伏西尔(TBPM-PI)在治疗儿童细菌性肺炎中的作用。同时收集痰和鼻咽拭子,并通过常规细菌培养鉴定致病菌,并通过实时聚合酶链反应(PCR)鉴定详尽的细菌和病毒。受试者为2006年10月至2007年6月间在Sotobo儿童诊所门诊诊断为轻度或中度肺炎的八名患者。TBPM-PI的建议临床剂量为4 mg / kgb.i.d。以5 mg / kg b.i.d的高剂量治疗5例患者给三个病人。从所有患者中收集痰液,并从洗过的痰液培养物中检测到11个菌株。致病菌主要是(3株)和(6株),鼻咽拭子显示出与咳嗽痰相同的微生物。通过实时PCR对单个病毒进行鉴定,确定了4例仅细菌感染,1例合并感染,2例病毒合并感染以及1例病毒和合并感染病例。临床结果表明对所有患者均有效,并且消除了病原体100%。在仅有细菌感染的四名患者中,治疗开始时的平均发烧38.9°C次日恢复正常,显示出优异的疗效。没有发生临床上有问题的不良事件,依从性良好。我们认为这些案例为儿童肺炎的病原性生物的鉴定以及TBPM-PI在门诊治疗中的可能作用提供了有价值的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号